New drug combo shows promise for rare breast cancer type
NCT ID NCT05919108
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial is testing whether the drug neratinib, given before standard treatment, can improve outcomes for people with stage I-III HER2-mutated lobular breast cancer. Neratinib blocks a protein that helps cancer cells grow. The study will enroll 30 participants and measure how well the cancer responds, including changes in tumor activity and the need for breast-conserving surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Neratinib (a kinase inhibitor taken by mouth)
- What this could lead to
- If successful, this could show that adding neratinib before standard therapy improves treatment response for people with this specific type of breast cancer.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply broadly. Neratinib can cause side effects like diarrhea and liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor College of Medicine
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Emory University/ Winship Cancer Institute
NOT_YET_RECRUITINGAtlanta, Georgia, 30322, United States
-
University of Pittsburgh Medical Center
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15213, United States
-
University of Texas, Southwestern
RECRUITINGDallas, Texas, 75390, United States
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37203, United States